HighGravityDataSigned in · PRO
Guidance history, every release
Raised · a change from the previous releaseSame · restated unchanged— · not stated in that releaseEvery value links to its sentence in the filing
| Metric | Oct 17, 2024 FY24 Q3 | Feb 12, 2025 FY24 Q4 | May 1, 2025 FY25 Q1 | Jul 31, 2025 FY25 Q2 | Oct 29, 2025 FY25 Q3 | Feb 10, 2026 FY25 Q4 | May 6, 2026 FY26 Q1 | Aug 5, 2026 FY26 Q2 |
|---|---|---|---|---|---|---|---|---|
| For FY2026 | ||||||||
| Total revenues | — | — | — | — | — | — | New“At least $405.0” | Raised“At least $414.0” |
| Adjusted EPS | — | — | — | — | — | New“$7.00 to $7.20” | Raised“$7.30 to $7.50” | Raised“$7.90 to $8.10” |
| Diluted earnings per share | — | — | — | — | — | — | New“$6.24-$6.44” | Raised“$6.84-$7.04” |
| GAAP diluted EPS | — | — | — | — | — | New“$5.94 to $6.14” | Raised“$6.24 to $6.44” | Raised“$6.84 to $7.04” |
| Net income attributable to CVS Health (GAAP measure), Per Common Share | — | — | — | — | — | New“$ 5.94” – “$ 6.14” | — | — |
| Net income attributable to CVS Health (GAAP measure), Total Company | — | — | — | — | — | New“$ 7,638” – “$ 7,892” | — | — |
| Adjusted income attributable to CVS Health, Per Common Share | — | — | — | — | — | New“$ 7.00” – “$ 7.20” | — | — |
| Adjusted income attributable to CVS Health, Total Company | — | — | — | — | — | New“$ 8,998” – “$ 9,252” | — | — |
| Cash flow from operations | — | — | — | — | — | New“at least $9.0 billion” | Raised“at least $9.5 billion” | Raised“at least $11.5 billion” |
| Weighted average diluted shares outstanding () | — | — | — | — | — | New“1,285” | — | — |
| For FY2025 | ||||||||
| Adjusted EPS | — | New“$5.75 to $6.00” | Raised“$6.00 to $6.20” | Raised“$6.30 to $6.40” | Raised“$6.55 to $6.65” | — | — | — |
| Adjusted EPS | — | — | New“$6.00” – “$6.20” | Raised“$ 6.30” – “$ 6.40” | — | — | — | — |
| Adjusted income attributable to CVS Health (Adjusted EPS) - Per Common Share | — | — | — | — | New“$ 6.55 to $ 6.65” | — | — | — |
| GAAP diluted earnings (loss) per share | — | — | — | — | New“$(0.34) to $(0.24)” | — | — | — |
| GAAP diluted EPS | — | New“$4.58 to $4.83” | Lowered“$4.23 to $4.43” | Lowered“$3.84 to $3.94” | — | — | — | — |
| GAAP diluted EPS | — | — | New“$4.23” – “$4.43” | Lowered“$ 3.84” – “$ 3.94” | — | — | — | — |
| Net income attributable to CVS Health (GAAP measure) - Per Common Share | — | New“$4.58 to $4.83” | — | — | — | — | — | — |
| Net income attributable to CVS Health (GAAP measure), Total Company | — | — | — | New“$ 4,883” – “$ 5,009” | — | — | — | — |
| Net income attributable to CVS Health, Total Company | — | — | New“$5,372” – “$5,624” | — | — | — | — | — |
| Adjusted income attributable to CVS Health - Per Common Share | — | New“$5.75 to $6.00” | — | — | — | — | — | — |
| Adjusted income attributable to CVS Health, Total Company | — | — | New“$7,620” – “$7,872” | Raised“$ 8,004” – “$ 8,130” | — | — | — | — |
| Cash flow from operations | — | New“approximately $6.5 billion” | Raised“approximately $7.0 billion” | Raised“at least $7.5 billion” | Revised“a range of $7.5 billion to $8.0 billion” | — | — | — |
| Net loss attributable to CVS Health (GAAP measure) - Per Common Share | — | — | — | — | New“$ (0.34) to $ (0.24)” | — | — | — |
| For FY2024 | ||||||||
| Adjusted EPS | New“$1.05” – “$1.10” | — | — | — | — | — | — | — |
| Adjusted EPS (preliminary) | New“$1.05 to $1.10” | — | — | — | — | — | — | — |
| GAAP diluted EPS | New“$0.03” – “$0.08” | — | — | — | — | — | — | — |
| GAAP diluted EPS (preliminary) | New“$0.03 to $0.08” | — | — | — | — | — | — | — |
| Medical Benefit Ratio (MBR) | New“approximately 95.2%” | — | — | — | — | — | — | — |
| Weighted average diluted shares outstanding | New“1,259” | — | — | — | — | — | — | — |
Values in quotation marks are the company’s words. Change labels compare each statement with the same metric and target year in the previous release. HighGravityData does not judge whether guidance was met.